You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 15, 2024

Investigational Drug Information for Treosulfan


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Treosulfan?

Treosulfan is an investigational drug.

There have been 46 clinical trials for Treosulfan. The most recent clinical trial was a Phase 3 trial, which was initiated on October 1st 2009.

The most common disease conditions in clinical trials are Leukemia, Myelodysplastic Syndromes, and Preleukemia. The leading clinical trial sponsors are medac GmbH, Fred Hutchinson Cancer Research Center, and National Cancer Institute (NCI).

Recent Clinical Trials for Treosulfan
TitleSponsorPhase
Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage SyndromeFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyPhase 2
PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of ImmunityFederal Research Institute of Pediatric Hematology, Oncology and ImmunologyPhase 2
Phase III Study Comparing GVHD Prophylaxis With ATG-thymoglobulin to ATLG-grafalon in Elderly Patients With Acute Myeloid Leukemia or Myelodysplasic Syndrome and Receiving an Allogeneic Hematopoietic Stem Cell Transplantation With a 10/10 HLA MatcheAssistance Publique - Hôpitaux de ParisPhase 3

See all Treosulfan clinical trials

Clinical Trial Summary for Treosulfan

Top disease conditions for Treosulfan
Top clinical trial sponsors for Treosulfan

See all Treosulfan clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.